Phase II study of 4SC-202 in combination with checkpoint inhibitors in patients with advanced melanoma who are refractory to treatment with checkpoint inhibitors
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs 4SC 202 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 May 2017 According to a 4SC media release, results from this study are expected in 2018.
- 29 Mar 2017 According to a 4SC media release, company is planning to initiate this trial in 2017.
- 06 Apr 2016 New trial record